Sanofi restructures its immuno-oncology collaboration with Regeneron Pharmaceuticals, Inc. Under the amended and restated license and collaboration agreement, Regeneron will obtain worldwide exclusive license rights to Libtayo. The Sanofi and Regeneron global immuno-oncology license and collaboration agreement was .
Sanofi grants Regeneron worldwide exclusive license rights to Libtayo (cemiplimab) Sanofi will receive an upfront payment of $900 million, and an 11% royalty on worldwide net sales of LibtayoSanofi
/PRNewswire/ Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its intent to purchase Sanofi s stake in the Regeneron and Sanofi collaboration.